CD4 and rheumatoid arthritis: As shown in Figure 5a, relative binding of Tregalizumab (ratio of MFIs between BT-061 and the non-competing anti-CD4 antibody SK3) in RA patients is significantly (P<0.0001) lower (6.9±1.6, n=127) compared with healthy subjects (8.3±0.8, n=35).